Anatomic Pathology Service, Hospital Universitario Marqués de Valdecilla/IDIVAL, Universidad de Cantabria, Santander, Spain; Translational Hematopathology Lab, IDIVAL, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Santander, Spain.
Radiology Service, Hospital Universitario Marqués de Valdecilla, Santander (Cantabria), Spain.
Rev Esp Patol. 2024 Jan-Mar;57(1):42-47. doi: 10.1016/j.patol.2023.01.002. Epub 2023 Feb 28.
Subsequent to mass vaccination programs against COVID-19, diverse side effects have been described, both at the injection site, such as pain, redness and swelling, and systemic effects such as fatigue, headache, muscle or joint pain. On rare occasions, a lymphadenopathic syndrome may develop, raising the clinical suspicion of a lymphoproliferative disorder. We present the case of a 30-year-old woman who developed self-limiting left axillary lymphadenopathy following COVID-19 vaccination. To date, only seven similar cases with a complete clinicopathological description have been published, and fourteen cases have been notified to the European adverse events databases (Eudravigilance) in relationship with vaccination against COVID-19. It is important to be aware of this potential complication when a lymphadenopathic syndrome develops following vaccination, to avoid unnecessary treatment.
在针对 COVID-19 的大规模疫苗接种计划之后,已经描述了多种副作用,包括在注射部位的副作用,如疼痛、发红和肿胀,以及全身性副作用,如疲劳、头痛、肌肉或关节疼痛。在极少数情况下,可能会出现淋巴结病综合征,引起对淋巴增生性疾病的临床怀疑。我们报告了一例 30 岁女性,在 COVID-19 接种疫苗后出现自限性左侧腋窝淋巴结病。迄今为止,只有 7 例具有完整临床病理描述的类似病例已发表,并且在与 COVID-19 疫苗接种相关的欧洲不良事件数据库 (Eudravigilance) 中已经报告了 14 例病例。当接种疫苗后出现淋巴结病综合征时,需要注意这种潜在的并发症,以避免不必要的治疗。